Monday, 31 August 2026European Markets

GROUPE JAJ Stock Went Down By Over 9% So Far On Tuesday

Loading stream...

groupe jaj, listed on the cac 40 as gjaj.pa, experienced its share price fall 9.03% by 11:52 am et tuesday to eur1.31. this drop follows two consecutive sessions of declines for this clothing distributor.

contradiction in market trends?

however, the overall cac 40 index experienced a modest gain of 0.16% to eur7,439.26, seemingly contradicting groupe jaj shares' downward momentum and showing that france remains on an upward trend despite groupe jaj stock value decline.

financial performance

groupe jaj, known for distributing schott brand clothing, reported 12-month earnings per share (eps) of eur0.24, signalling modest profitability for the firm. when considered alongside its price-to-earnings (p/e) ratio of 5.46, investors effectively paid eur5.46 per euro of groupe jaj's annual earnings when their shares were acquired.

investor sentiment

groupe jaj saw its trading volume for the day reach 8,255, an astonishing increase of 516.5% compared to its usual volume of 1,339. this sudden surge may signal investor fear about its future prospects and prompt increased selling action from shareholders.

important considerations for investors

investors would do well to pay attention to these events as they can provide a key window into the company's finances and market sentiment.

more news about groupe jaj (gjaj.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com